Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - AUXILIUM PHARMACEUTICALS INC | d255092d8k.htm |
 1
November 2011
(NASDAQ: AUXL)
Exhibit 99.1 |
 2
Safe Harbor Statement
We
will
make
various
remarks
relating
to
our
current
plans,
potential
future
events,
and
what
we
believe
to
be
the
prospects
for
the
Company
during
this
conference
call
that
constitute
forward-looking
statements
for
purposes
of
the
Safe
Harbor
provisions
under
the
Private
Securities
Litigation
Reform
Act
of
1995.
Today
our
forward-looking
statements
will
cover,
among
other
things,
the
Company’s
expected
financial
performance,
results
and
strategic
priorities
during
2011;
the
impact
of
organizational
changes;
marketing
strategies
for
XIAFLEX
for
Dupuytren’s
contracture;
the
potential
for
XIAFLEX
to
change
the
treatment
paradigm
and
become
the
standard
of
care
for
the
treatment
of
Dupuytren’s;
the
size
of
the
Dupuytren’s
market;
the
durability
of
XIAFLEX
treatment
outcomes;
future
rates
of
recurrence;
a
clinical
trial
to
assess
multiple
concurrent
injections
of
XIAFLEX
and
the
timing
to
report
results
of
such
trial;
the
value
for
XIAFLEX
provided
by
the
2012
Medicare
national
average
reimbursement
rates
for
new
procedure
codes
and
the
effect
of
new
procedure
codes
on
the
reimbursement
process
and
XIAFLEX
growth;
reductions
in
Medicare
payment
rates
in
accordance
with
the
SGR
formula
for
2012;
the
effect
of
the
identified
leading
indicators
on
the
success
of
the
XIAFLEX
launch
and
future
net
revenues;
additional
Phase
IV
clinical
trials
for
XIAFLEX;
peer
to
peer
dialogue
programs
for
U.S.
physicians
and
our
U.S.
patient
education
campaign;
Pfizer’s
ability
to
commercialize
XIAPEX
for
Dupuytren’s
contracture
in
EU
and
Eurasian
markets;
Asahi
Kasei
Pharma's
ability
to
develop,
register
for
approval
and
commercialize
XIAFLEX
for
Dupuytren's
contracture
and
Peyronie's
disease
in
Japan;
the
potential
for
XIAFLEX
to
be
used
in
multiple
indications,
including
for
the
treatment
of
Peyronie’s,
cellulite,
Frozen
Shoulder
syndrome
and
canine
and
human
lipomas,
the
effectiveness
of
XIAFLEX
for
any
such
indications,
and
the
success
of
efforts
to
advance
any
such
new
indications;
the
design
and
methodology,
and
the
timing
to
report
results,
of
the
phase
III
trials
for
XIAFLEX
for
the
treatment
of
Peyronie’s;
the
Peyronie’s,
Frozen
Shoulder
and
cellulite
markets;
the
timing,
commencement,
methodology,
safety
and
efficacy
of
planned
clinical
trials
for
XIAFLEX
for
the
treatments
of
cellulite,
Frozen
Shoulder
syndrome,
and
human
and
canine
lipomas;
our
future
relationship
with
BioSpecifics
Technologies
Corp.;
the
growth
of
the
testosterone
replacement
therapy
market,
and
the
growth
opportunity
for
Testim;
business
development
efforts
and
opportunities
to
build
out
the
Company’s
pipeline;
our
ability
to
maximize
the
value
of
XIAFLEX
and
Testim,
deliver
on
our
current
pipeline,
build
out
our
pipeline
and
create
shareholder
value.
Actual
results
may
differ
materially
from
those
reflected
in
these
forward-looking
statements
due
to
various
factors,
including
general
financial,
economic,
regulatory
and
political
conditions
affecting
the
biotechnology
and
pharmaceutical
industries
and
those
discussed
in
Auxilium's
Annual
Report
on
Form
10-K
for
the
year
ended
December
31,
2010
and
Quarterly
Report
on
Form
10-Q
for
the
quarter
ended
September
30,
2011
under
the
heading
“Risk
Factors,”
which
are
on
file
with
the
Securities
and
Exchange
Commission
(the
“SEC”)
and
may
be
accessed
electronically
by
means
of
the
SEC’s
home
page
on
the
Internet
at
http://www.sec.gov
or
by
means
of
the
Company’s
home
page
on
the
Internet
at
http://www.auxilium.com
under
the
heading
“For
Investors
-
SEC
Filings.”
There
may
be
additional
risks
that
the
Company
does
not
presently
know
or
that
the
Company
currently
believes
are
immaterial
which
could
also
cause
actual
results
to
differ
from
those
contained
in
the
forward-looking
statements.
Given
these
risks
and
uncertainties,
any
or
all
of
these
forward-looking
statements
may
prove
to
be
incorrect.
Therefore,
you
should
not
rely
on
any
such
factors
or
forward-
looking
statements.
In
addition,
forward-looking
statements
provide
the
Company’s
expectations,
plans
or
forecasts
of
future
events
and
views
as
of
the
date
of
this
presentation.
The
Company
anticipates
that
subsequent
events
and
developments
will
cause
the
Company’s
assessments
to
change.
However,
while
the
Company
may
elect
to
update
these
forward-looking
statements
at
some
point
in
the
future,
the
Company
specifically
disclaims
any
obligation
to
do
so.
These forward-
looking
statements
should
not
be
relied
upon
as
representing
the
Company’s
assessments
as
of
any
date
subsequent
to
the
date
of
this
presentation.. |
 3
Our Vision Is to Become a Rapidly Growing,
Profitable and Sustainable Biopharmaceutical
Company
Maximize Value of
Testim
®
and XIAFLEX
®
Deliver on
Current Pipeline
Build Out
Pipeline in
Specialty
Therapeutic
Areas |
 4
XIAFLEX and Testim Are Global Product
Opportunities
U.S.
Canada
EU
Japan
Open
ROW
Open
Open
Territory
XIAFLEX
Testim |
 5
Auxilium Has a 6 Year Net Revenue CAGR
of 39.4%
3Q11 XIAFLEX Net
Revenues $13.1M
(including $10.3M in U.S.
revenues)
124% y/y growth
3Q11 Testim U.S. Net
Revenues $52.9M,
12% y/y growth |
 6 |
 7
•
Excessive collagen in fascia of hand
•
Nodules or pits are an early, active
presentation
•
Rope-like cords develop in the finger
and result in contractures
•
Quality of life and daily activities
affected
•
Surgery has been reserved for
advanced disease due to the nature of
the disease, unpredictable results,
complications, long recovery time and
recurrence/additional surgeries
Dupuytren’s Contracture Is Debilitating for Patients
and Surgery Has Been the Standard of Care
Immediately post-operative
Intra-operative open fasciectomy
Pictures courtesy
of Dr. Clayton Peimer
pre-operative open fasciectomy |
 8
We Believe XIAFLEX Is a Paradigm
Changing Treatment
•
Simple, non-invasive injection of XIAFLEX
•
Established mechanism of action and selective for specific types of collagen
•
XIAFLEX’s post-approval profile is consistent with clinical trial
experience Pre XIAFLEX injection
30 days following XIAFLEX
injection |
 9
Strategies for Establishing XIAFLEX as the
Standard of Care
•
Leverage excellent clinical efficacy/safety data
•
Generate new data to expand treatable population
•
Facilitate peer to peer dialogue
•
Streamline the reimbursement process
•
Activate patients to seek a non-surgical option |
 10
Commercial Changes Designed to Speed
Decision Making and Improve Xiaflex
Performance
•
Eliminated
EVP of Sales and Marketing position
•
SVP Sales, and SVP Marketing will report to CEO
•
Changed Professional Advertising Agency and Public
Relations Firm
•
Changed Senior Director of Marketing |
 11
XIAFLEX Growth Strategy is Tailored to
Customer Needs
•
~ 6,000 target physicians
–
Hand surgeons, plastic surgeons, orthopedic
surgeons, general surgeons, rheumatologists
•
~ 100 field based personnel
–
Sales reps, sales managers, and reimbursement
specialists
•
Medical science liaisons
–
Key opinion leader and regional opinion leader
support |
 12
We Believe the U.S. Dupuytren’s Opportunity Is
Significant
70,000 Surgical
2,3,4
Patients Annually
300,000 Diagnosed
Patients Annually
2,3,4
>1 Million Diagnosed
Patients
2,4
1.
Dupuytren’s
Disease
–
Tubiana,
LeClerq,
Hurst,
Badalamente,
Mackin
2.
SDI
Claims
Data
Based
Projections
3.
Medicare
Data
Based
Projections
(BESS
database
used,
Medicare
5%
database
also
used
to
validate
numbers)
4.
Auxilium
Research
(Patient
Segmentation,
Forecast
Research,
WK/AMA
Databases)
Sources:
$350 Million
Market
Opportunity
$1 Billion
Annual Market
Opportunity
>$3 Billion Market
Opportunity |
 13
Highlights of Data Released at ASSH Meeting |
 14
Building on Momentum from ASSH
•
Introduced Sample program for non-using physicians
•
Introduced Patient co-pay assistance program
•
Initiated Direct Response TV Campaign in 7 Ready Markets
•
Initiated Multi-Cord Phase IV clinical study
•
Obtained CPT Codes Specific for Xiaflex –
Effective Jan.1, 2012
•
Obtained Coverage at several BCBS Plans |
 15
Launch Update Through
October 2011 |
 16
Leading Indicators Trending Positively
-
Cumulative Enrollment & sites that have ordered XIAFLEX
|
 17
Paradigm Changing Progress
Cumulative Injections per Site |
 18
2012 Average Medicare Reimbursement Rates
for Unique XIAFLEX Procedure Codes*
Expected to Provide Appropriate Value
Description
Code
Amount
Office or other outpatient visit, for
the evaluation and management of a
new patient
99203
$102.95
INJECTION, ENZYME (EG,
COLLAGENASE), PALMAR FASCIAL
CORD (IE, DUPUYTREN'S
CONTRACTURE)
20527
$75.77
Finger Extension- MANIPULATION,
PALMAR FASCIAL CORD (IE,
DUPUYTREN'S CORD), POST ENZYME
INJECTION (EG, COLLAGENASE),
SINGLE CORD (10 day global)
26341
$98.53
Application of finger splint; static
29130
$39.07
*The above codes represent what the Company expects will be the typical treatment cycle (evaluation
& management visit, injection procedure, manipulation procedure and splinting) of a new
Dupuytren’s patient who eventually receives a single XIAFLEX injection in a
Dupuytren’s cord. These 2012 rates reflect a national Medicare average of the
non-facility allowable. As always, coding reflects clinical decisions, and physicians
may opt to use other or additional codes based on their medical judgment. The above rates are calculated using the
final 2012 relative value unit (RVU) for each of the above codes and multiplying it by the 2011
conversion factor (i.e. RVU x conversion factor = reimbursement rate). Without a change
in the law from Congress, Medicare payment rates to providers that are paid under the Medicare
Physician Fee Schedule will be reduced by 27.4 percent (via the proposed 2012 conversion factor) for
services in 2012. This is the eleventh time the Sustainable Growth Rate (SGR) formula has
proposed a payment cut although the reductions have been averted through legislation in ten of
the past eleven years, with the exception of allowing the reduction to stand in 2002. |
 19
New CPT Codes for XIAFLEX Should Help
Streamline Reimbursement in 2012
•
We believe the codes should ease the reimbursement
processing burden on office staff, speed up the time to
payment and increase predictability of payment.
•
Based on experience with the J-code, we believe full
utilization of the new CPT codes could take some time
before affecting site reimbursement practices
•
2012 XIAFLEX growth should be helped modestly by
new CPT codes |
 20
Testim
®
1% Testosterone Gel
•
Indicated for testosterone replacement therapy in adult
males for hypogonadism
•
Launched in U.S. in 2003 and EU in 2006
•
>8 yrs of use with established safety and efficacy
•
Applied once daily at 5-10mg
>
90% stay on starting dose of 5mg (one tube)
>
Simple application process and dosing
>
~100M
daily
doses
since
launch
>
16
clinical
studies
involving
approx.
1,800
patients |
 21
Hypogonadism Is an Unmet Need and
Under-penetrated Market
•
39%
of
U.S.
males
over
45
yrs
are
hypogonadal
1
>
Less
than
10%
of
affected
population
receives
treatment
•
Increasing
physician
and
patient
education
and
awareness
should
result
in
increased
treatment
1
Mulligan T. et al. Int J. Clin Pract
2006 |
 22
Gels Continue to Drive Significant Growth in
TRT Marketplace
Source: IMS data
$35
$117
$198
$281
$334
$371
$439
$545
$685
$892
$1,149
$49
$59
$77
$118
$210
$302
$390
$451
$483
$554
$663
$810
$1,041
0
200
400
600
800
1,000
1,200
1,400
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
Gel
Patch
Oral
Injectables
($ in millions)
$1,329 |
 23
Testosterone Replacement Therapy Landscape
is Changing
•
New competition helping expand treated market
in 2011 with 17% y/y growth from 3Q10
•
Maintaining solid market share (21%) due to
blunting of competitor launch tactics
•
Testim has expanded covered lives through
some wins in managed care |
 24
XIAFLEX Pipeline |
 25
XIAFLEX Represents a Pipeline in a Product
-
U.S. patent protected through 2028
PRODUCT
LATE RESEARCH
PRE-CLINICAL PHASE I PHASE II PHASE
III MARKET
XIAFLEX
XIAFLEX
XIAFLEX
XIAFLEX
XIAFLEX
XIAFLEX
Dupuytren’s Contracture
Peyronie’s Disease
Frozen Shoulder Syndrome
Canine Lipoma*
Human Lipoma*
Cellulite*
*Right to exercise option for exclusive global license from BioSpecifics
Technologies Corp. |
 26
1
Smith BH. Am J Clin Pathol. 1966;45:670-678.
2
Somers KD, Dawson DM. J Urol. 1997;157:311-315.
•
Scarring phenomenon affecting the
tunica albuginea
1
•
Plaques show excessive collagen deposition
2
•
Potential Symptoms
>
Pain with erection, penile curvature/
deviation, penile shortening, indentations,
and/or erectile dysfunction
>
May experience difficulty with sexual
intercourse, loss of self-esteem,
and depression
Peyronie’s disease Is a Devastating Disorder
with No Approved Therapies |
 27
1
Bella
A.
Peyronie’s
Disease
J
Sex
Med
2007;4:1527–1538
2
Lue
TF,
et
al.
Summary
of
the
recommendations
on
sexual
dysfunctions
in
men.
J
Sex
Med
2004;1:6–23.
3
Mulhall
JP,
et
al.
Subjective
and
objective
analysis
of
the
prevalence
of
Peyronie’s
disease
in
a
population
of
men
presenting
for
prostate
cancer
screening.
J
Urol
2004;171:2350–3.
4
Smith
BH.
Am
J
Clin
Pathol.
1966;45:670-678.
5
Lindsay
MB,
J
Urol.
1991;146:1007-1009.
6
Nyberg
L,
J
Urol.128:
48,
1982
•
Prevalence of Peyronie’s disease is estimated to be approximately
5%
in
adult
men
1,2,3
>
Actual
prevalence
may
be
higher,
based
on
autopsies
4
•
Prevalence
rate
increases
with
age
>
The
average
age
of
disease
onset
is
53
years
5
•
High
association
with
other
diseases
such
as:
>
Diabetes,
erectile
dysfunction
(ED),
Dupuytren’s
contracture,
plantar
fascial
contracture,
tympanosclerosis,
gout,
and
Paget’s
disease
6
We believe Peyronie’s Disease Is Under-
diagnosed and Under-treated |
 28
Peyronie’s Disease Phase III Development
Program
Study
Type
~ #
Subjects
Sites
XIAFLEX:
Placebo
Duration
AUX-CC-803
Double-blind,
placebo controlled
400
~ 30 US
5 AUS
2:1
52 Wks
AUX-CC-804
Double-blind,
placebo controlled
400
~ 30 US
5 AUS
2:1
52 Wks
AUX-CC-802
Open Label
300
12 US
6 NZ
~ 21 EU
N/A
36 Wks
AUX-CC-805
Pharmacokinetics
20
1 US
N/A
4 Wks
XIAFLEX 0.58 mg
Two injections per treatment cycle
24 to 72 hours between injections
Penile plaque modeling following each cycle
Up to 4 cycles at 6 week intervals
Co-primary endpoints of disease bother and penile curvature
|
 29
We Believe Changes to the Phase IIb Trial Design
Should Increase the Chance of Success in Phase III
•
4 cycles of therapy in the phase III trial
•
All patients receive modeling
•
All patients must have at least 12 months of
disease since diagnosis
Mean net improvements in phase IIb penile
curvature and bother domain would have met
statistical significance using phase III co-primary
endpoint requirements |
 30
Baseline Characteristics in the Phase III Double-
blind Trials are Similar to the Phase IIb Clinical
Trial
•
Phase III baseline curvature and Peyronie’s disease bother
are comparable to the phase IIb baseline.
•
Degree of penile curvature deformity did not correlate with PD
bother at baseline (e.g. low curvature may result in high PD
bother and vice-versa)
•
The majority of patients with penile curvature =60°
or >60°
were:
–
very
bothered
or
extremely
bothered
the
last
time
they
looked
at
their
erect penis (58% and 73%, respectively)
–
reported difficulty in having vaginal intercourse (70% and 76%,
respectively)
–
reported having sexual intercourse less frequently (81%)
•
A significant correlation exists between PD bother and patient
reported distress. |
 31
Peyronie’s Pivotal Phase III Update
•
Active dosing phase complete
•
Double-blind patients are now in the 34 week
follow-up phase of studies
•
Top line results in Peyronie’s should be
available in 2Q12 |
 32
Collagen Septae Enable Edematous
Fibrosclerotic Panniculopathy (EFP)
Cellulite
Collagen Network |
 33
EFP Represents an Unmet Medical Need
•
Current non-surgical treatment options have not shown benefit in EFP
–
OTC pills, creams and lotions.
–
Unapproved mixtures of enzymes and fat dissolvers
–
Various devices, including lasers
•
There are currently no FDA approved medical therapies for EFP
•
Surgical approaches have shown some benefit, but are invasive
–
Liposuction
–
Subscision
•
We believe XIAFLEX may enable physicians to enzymatically and
specifically lyse the septae, in a less invasive fashion than subscision,
possibly resulting in a smoother appearance to the skin surface.
|
 34
Early Pilot Phase I Trial was Encouraging
•
Drs. Dagum and Badalamente at SUNY Stony Brook
•
10 female subjects were treated with a single 0.58 mg dose of collagenase
•
76% reduction in the physician reported appearance of cellulite and a patient
satisfaction score of 1.75 at 6 months
–
Scale for the patient satisfaction scoring ranged from 1 being completely
satisfied and 4 being not satisfied |
 35
Considerable Work Done in Cellulite
•
Pre-IND meeting with FDA to determine a
path forward
•
Pre-clinical work done with subcutaneous
injections of XIAFLEX at variable doses in
a mini-pig study
–
Lysis of collagen in dermal septae was
observed at all doses
•
Completing stability work on new diluent
and dosage formulations
•
Preparation for the filing of an IND in the
4Q11 |
 36
Cellulite –
Phase Ib Dose Escalation Study
•
Expected to begin in 1Q12
•
Assess the safety and efficacy of XIAFLEX in the
treatment of cellulite
–
Multiple doses in various volumes and concentrations
–
10 injection
sites over an 8 x 10cm surface area
–
Seven cohorts followed for 90 days
•
Physician and patient reported improvement of
cellulite endpoints
•
Topline results expected in 4Q12 |
 37
Collagen Accumulation Can Result in
Adhesive Capsulitis
Normal Shoulder
Frozen Shoulder |
 38
Adhesive Capsulitis Represents an Unmet
Medical Need
•
Current treatment options have limited results
–
non-steroidal pain relievers
–
oral steroids
–
corticosteroid injections
–
physical therapy all with limited results.
•
Manipulation of the shoulder under anesthesia or arthroscopic
surgery can disrupt the frozen capsule
•
There are currently no FDA approved non-surgical therapies for
Frozen Shoulder
•
We believe that XIAFLEX may act by thinning the thickened
collagen capsule allowing improved range of motion of the affected
shoulder. |
 39
Early Pilot Phase II Trial was Encouraging
•
Drs. Wang and Badalamente at SUNY Stony Brook
–
60 subjects treated with varying doses of collagenase
–
Following a single injection of collagenase, 8 subjects in the collagenase groups
or approximately 16% achieved successful treatment outcomes
–
In the subsequent open label portion, 46 subjects received additional injections
of 0.58 mg of collagenase up to a total of 4 injections
–
By the third injection, 43 of the 46 subjects in the open label extension or 93%,
had achieved a response with increased shoulder motion
•
Saline injection study
–
Injected sterile saline under ultrasound guidance
–
All subjects confirmed appropriate location of injection as extraarticular
|
 40
Frozen Shoulder –
Phase IIa Dose
Escalation Study
•
To assess the safety and efficacy of XIAFLEX in the
treatment of Frozen Shoulder
–
Two doses (0.29 and 0.58 mg) given under ultrasound guidance
–
Approximately 50 subjects across 5 cohorts
–
Up to three injections 21 days apart
–
Subjects followed for 90 days
•
Endpoint will be range of motion parameters for the
affected shoulder
•
Topline results expected in the 1H13 |
 41
BTC Will Advance Clinical Studies in Canine
and Human Lipomas
•
Lipomas consist of normal fat encapsulated
within a collagen capsule or shell
•
Current treatment options for lipoma include
liposuction or surgical excision
•
There are no approved non-surgical
therapies
•
We believe XIAFLEX may be beneficial in
lysing that collagen capsule allowing
redistribution of the normal fat and reduction
or disappearance of the palpable lipoma |
 42
XIAFLEX –
Additional Data and Development
Work Ongoing
•
Some small pilot studies were conducted examining the effects of
collagenase on lipomas in humans and animals.
•
Investigators noted improvement in lipomas, specifically reduction in
their size, following injections of collagenase.
•
BTC is planning a pilot dose escalation study with treatment of
benign lipomas with XIAFLEX in 14 human subjects.
•
BTC is planning a study in 32 canines in which they will examine
several doses for the treatment of benign lipomas with
XIAFLEX. |
 43
Business Development Efforts Expected to
Focus on Building Out Pipeline
•
Leverage current infrastructure of Testim and
XIAFLEX field forces with additional marketed
products
•
Seeking assets in Urology, Orthopedics and
Orphan Diseases |
 44
Net Revenues Up 24% over 3Q10
Quarter End
Quarter End
Increase
9/30/2011
9/30/2010
(Decrease)
Testim U.S. Revenue
$52.9
$47.4
$5.5
Testim Ex – U.S. & Contract Revenue
0.7
0.5
0.2
Total Testim Revenue
$53.6
$47.9
$5.7
XIAFLEX U.S. Revenue
$10.3
$4.6
$5.7
XIAFLEX Ex – U.S. and Contract Revenue
$2.8
1.1
1.7
Total XIAFLEX Revenue
$13.1
$5.7
$7.4
Total Worldwide Revenue
$66.7
$53.6
$13.1 |
 45
3Q11 Financial Results ($ Millions)
(Decr.)
3Q11
3Q10
$
%
Total Revenues
$ 66.7
$ 53.6
$ 13.1
24%
Cost of Goods Sold *
$ 13.5
$ 11.6
$ 2.0
17%
Gross Profit
$ 53.2
$ 42.1
$ 11.1
26%
% of Revenues
80%
78%
R & D Expense *
$ 14.2
$ 14.4
$ (0.3)
(2%)
SG&A Expense *
$ 43.3
$ 40.3
$ 2.9
7%
Net Loss
$ (4.1)
$ (12.8)
$ 8.7
68%
Earnings per share
$ (0.08)
$ (0.27)
$ 0.18
68%
* Stock Based
Comp Expense
$ 3.8
$ 3.5
$ 0.3
10%
Cash & Cash
Equivalents
$ 149.6
Incr. / |
 46
2011 Guidance
Global Testim Revenues
$200 -
210 million
Xiaflex:
US Revenues
45 -
50 million
Ex-U.S. / Def Rev*
9 -
11 million
Total Xiaflex
$54 -
61 million
Total Revenues
$254 -
271 million
R & D Expense
$60 -
70 million
S G & A Expense
$170 -
180 million
Net Income (Loss)
$(40) -
(45) million
Stock Base Comp Expense
$15 -
20 million
*Following Pfizer’s first sale in Spain, the third major market, we expect to
exceed the upper end of this guidance by $1 to 2 million. |
 47
We Believe That Auxilium is Well-Positioned
for Long-Term Growth
•
Establish XIAFLEX as the standard of care for Dupuytren’s contracture in
the U.S.
•
Maximize Testim in a changing competitive environment
•
Support Pfizer’s launch of XIAPEX for the treatment of Dupuytren’s
contracture
•
Complete the Peyronie’s Disease double blind studies and announce
top- line data in 2Q12
•
Initiate phase IIa clinical trial for Frozen Shoulder in 4Q11 and Phase Ib
trial for cellulite in early 2012
•
Work collaboratively with BTC to assist them as they initiate studies using
XIAFLEX |
 48
Our Vision Is to Become a Rapidly Growing,
Profitable and Sustainable Biopharmaceutical
Company
Maximize Value of
Testim and XIAFLEX
Deliver on
Current Pipeline
Build Out
Pipeline in
Specialty
Therapeutic
Areas |
 49
Management Contact
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com
William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
wsargent@auxilium.com |